RecruitingPhase 1Phase 2NCT07788118

A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Single-Arm Design Using a Historical Control (7×19 CAR-T)

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Enrollment

70 participants

Start Date

Sep 1, 2026

Study Type

INTERVENTIONAL

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Mantle Cell Lymphoma (MCL)Relapsed/Refractory Large B-cell Lymphoma (LBCL)Transforming Follicular Lymphoma (tFL)

Summary

This study is aimed to explored the safety and efficacy of 7×19-THEMIS CAR-T cell therapy for large B-cell lymphoma and to conduct an exploratory comparison of the 3-month objective response rate (ORR) and complete remission rate (CR rate) between the experimental cohort and the historical control cohort (NCT04833504).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called 7×19-THEMIS CAR-T cells for people with diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.